Similar findings were reported by Moscvin et al., who noted a higher frequency of deletions in the complement Factor H genes (delCFHR3‐CFHR1 and delCFHR1‐CFHR4) in MM patients with carfilzomib‐associated TMA compared to the general population and matched controls. This evidence concerns the gene CFHR1 and Miyoshi myopathy.